bobdroege7
Illuminator
- Joined
- May 6, 2004
- Messages
- 4,409
I think the studies referenced are fatally flawed for the following reasons
One, it presents a false dichotomy that there is only two types of prostate cancer, either the fast growing early onset type that killed Frank Zappa and the slow growing won't do you in at all type.
Second, it doesn't address the treatablity of prostate cancer very well. Is it a problem of the PSA and DRE tests that prostate cancer is not very tractable to treatment?
Surgery, radiation treatments of at least three different protocols that I know of as IANAD and numerous chemotherapy agents, indicate to me that there is not one treatment that is hands down better than anyother or effective even.
It compares the single shot PSA test against the no PSA test and does not encompass baseline PSA testing and PSA doubling time testing as a competative testing modality.
And lastly, I think the study encompasses too many subjects for not long enough period of time. I'd rather see a thousand patients in each cohort followed until death as long as it is ethical, meaning no denial of treatment.
Being in the group with a first degree relative who died of prostate cancer I may be too close the subject to be rational and objective but I am glad to know my PSA score is 0.1.
One, it presents a false dichotomy that there is only two types of prostate cancer, either the fast growing early onset type that killed Frank Zappa and the slow growing won't do you in at all type.
Second, it doesn't address the treatablity of prostate cancer very well. Is it a problem of the PSA and DRE tests that prostate cancer is not very tractable to treatment?
Surgery, radiation treatments of at least three different protocols that I know of as IANAD and numerous chemotherapy agents, indicate to me that there is not one treatment that is hands down better than anyother or effective even.
It compares the single shot PSA test against the no PSA test and does not encompass baseline PSA testing and PSA doubling time testing as a competative testing modality.
And lastly, I think the study encompasses too many subjects for not long enough period of time. I'd rather see a thousand patients in each cohort followed until death as long as it is ethical, meaning no denial of treatment.
Being in the group with a first degree relative who died of prostate cancer I may be too close the subject to be rational and objective but I am glad to know my PSA score is 0.1.